Arcus Biosciences’ 2026 Q2 Earnings Call: First-Line Data Maturity and Second-Line PFS Benchmarks Clash

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $41M gap revenue in Q2; full year 2026 expected $65-75M, driven by collaborations

Guidance:

• Cash and investments expected to end 2026 at ~$600M, providing runway into at least H2 2028.
• Gap revenue for full year 2026 expected to be $65 to $75 million.
• R&D spend expected to decrease meaningfully in 2026/2027, with >80% directed toward Castatafan in 2027.
• PRISM-1 Phase III pancreatic cancer trial data expected in H1 2027.
• Multiple immunology programs advancing into clinic, with INDs expected through end of 2027.

Business Commentary:

Casdatafan Development and Market Potential:

• Arcus reported substantial progress in advancing Casdatafan, with expectations of it becoming the foundational therapy in Clear Cell RCC, targeting a market potential of $5 billion to $10 billion.
• This advancement is driven by the drug's superior efficacy profile and strategic development plans, including partnerships with major pharmaceutical companies to explore various combination regimens.

Clinical Trial Progress and Data Readouts:

• Key clinical milestones include the completion of enrollment for the Phase III trial Peak 1 by the end of 2026 and the initiation of the first-line Phase III study Peak 20 by year-end.
• The positive data trends are attributed to the robust clinical data demonstrating Casdatafan's efficacy and safety advantages over existing treatments, bolstered by recent partnership expansions.

Financial Position and Strategic Collaborations:

• Arcus reported $775 million in cash and investments as of June 30, 2026, anticipating a cash runway into at least the second half of 2028.
• Strategic collaborations with companies like BMS, Summit, and Aveo are structured to advance Casdatafan combinations efficiently, minimizing capital expenditure while maximizing development opportunities.

Immunology Portfolio and Future INDs:

• The immunology portfolio is progressing with plans to initiate human dosing of several programs, aiming for a steady flow of INDs between now and the end of 2027.
• The focus on developing oral small molecule alternatives reflects a strategic emphasis on creating safe and effective treatments for autoimmune and allergic diseases.

Pancreatic Cancer Opportunity with Quemley:

• The Phase III PRISM-1 study for Quemley in pancreatic cancer is on track for a readout next year, representing a significant opportunity in the frontline treatment setting.
• The potential of Quemley as an all-comer, first-line treatment is underscored by its well-tolerated profile and ability to enhance the benefit of immunogenic chemotherapy.

Sentiment Analysis:

Overall Tone: Positive

• CEO states 'We continue to make substantial progress' and 'CAST has driven an inflection in value.' Highlights 'tremendous' progress, 'clear path' to become backbone therapy, and 'no competition' in frontline. Cash position provides 'runway' and 'well positioned to execute.'

Q&A:

• Question from Salim: Congrats on the progress, guys, and thanks for the question. Just one kind of going into all the October data, obviously a lot of data that we'll be getting, is there a bogey or measure of success that you're looking at in each of these lines that you would care to elucidate here for folks? And also, while we're there, are there any particular parts of the data set that you would place a little bit more prominence on where you want people to anchor to?
  Response: Success will be demonstrating Castatafan becomes the backbone standard across all lines. Key data points: Frontline safety and primary progression rate; second-line PFS and potential OS advantage over Cabo; late-line OS vs. Belzutafan. Data will provide holistic picture for investor conviction.

• Question from Dana Graybosh (LeeRinc Partners): Hi. Thanks for the question. Looking forward to another fall event. I wonder if you can talk about LightSpark 12, which we'll see at ESMO after that event, and your expectations for PFS and OS from that study increase your confidence that Cas can exceed. And is there a specific signal that would give you there with Axie in a PD-1 where Bells, Lemva, and Pembro failed? Thank you.
  Response: Confidence stems from Castatafan's durable HIF-2 inhibition vs. Belzutafan's waning effect. The failed LightSpark 012 highlights the importance of strong, sustained target inhibition. Arcus' molecule maintains inhibition, providing a robust mechanism against TKI-induced HIF-2 upregulation.

• Question from Jonathan Miller (Evercore ISI): Hi, guys. Thanks for taking my question. A couple more about what we're expecting in October. In the second line cohort, can you remind us how much TKIs are created equal? And we know that sequencing has effects. I think we've seen prior TKIs. Prior Lenvima, those patients have gotten, Terry, to your point, not eye treatment numbers, but how many patients got Lenvima prior? And then secondly, in first line cohort, I'm a little surprised that you're so hesitant about giving ORR or broader efficacy readouts for the triplet in first line. You'll have two scans or more for most patients. What do you expect to see for time to response in first line versus second line? Do you think that there won't be enough to at least start directionally talking about that? Why are you so hesitant to give ORR and why do you?
  Response: Not hesitant; will share ORR but prioritize safety and primary progression rate for the frontline triplet. For second-line cohort, will provide specific prior TKI/Lenvima patient numbers. The more critical data are the safety profile and the reduced primary progression rate, which are key differentiators.

• Question from Lee Wastick (Kantor): Hey guys, thanks for taking our questions and congrats on the progress. I have two questions. Maybe first to follow up on the lymph question for the second line Cas plus Cabo cohort, how should we think about the impact of prior lymph exposure on the types of patients you enrolled into the study relative to the LightSpark 11 trial, just trying to understand the right PFS benchmark given some differences in the patient population. And then second, Terry, you mentioned prior TKI exposure increases the HIF-2 levels. Just trying positive relationship with prior lines of TKI. to clarify if you're implying CASAS, PFAS has the...
  Response: Confident Castatafan benefits patients with prior TKI exposure, as late-line data showed no efficacy degradation. Will use sub-analyses from the Cabo Point trial to compare against both prior TKI and prior IOIO patients. Castatafan's durable HIF-2 inhibition is expected to provide greater benefit in this population.

Contradiction Point 1

Timing and Maturity of First-Line Study Data

Contradiction on the follow-up duration and maturity of the first-line CAS+Zim+Ipi cohort data.

Salim (Mizuho) - Salim (Mizuho)

2026Q2: Initial safety data, rate of primary progression... and PFS waterfall/spider plots from the ARC-20 cohort evaluating **Cas plus Zimberlimab plus Ipi**. - Terry Rosen(CEO)

"For the upcoming October data, what are the key metrics you're using to measure success for each line of therapy, and which specific parts of the dataset should we focus on?" - Jonathan Miller (Evercore ISI)

2026Q2: For the CAS+anti-PD-1 cohort (CAS+zim), **ORR and PFS curve** (with ~11 months follow-up) will be presented... - Terry Rosen(CEO)

Contradiction Point 2

Second-Line Study (CAS+Cabo) Data Maturity and Benchmark

Contradiction on the benchmark used to compare the CAS+Cabo study's PFS.

Salim (Mizuho) - Salim (Mizuho)

2026Q2: Mature ORR and PFS data from ~45 patients with ~18 months of follow-up, and an early read on OS. - Terry Rosen(CEO)

What specific measures of success are you using for each line of therapy in the October data, and which parts of the dataset should we focus on? - Lee Wastick (Kantor)

2026Q2: The **Cabo Point study** (a historical Cabo trial) provides a perfect internal benchmark... - Terry Rosen(CEO)

Contradiction Point 3

First-Line Study (CAS+Zim+Ipi) Data Priority

Contradiction on which data from the first-line registrational study is prioritized for presentation.

What is Dana Graybosh's role in LeeRinc Partners' earnings call? - Dana Graybosh (LeeRinc Partners)

2026Q2: The **most critical early readouts** are **safety** and the **rate of primary progression**... The **PFS curve shape**... will provide early insight... - Terry Rosen(CEO)

Can you provide an update on the LightSpark 012 study's PFS and OS expectations ahead of the ESMO event and how they may impact confidence in CasDataFan? - Jonathan Miller (Evercore ISI)

2026Q2: The goal is to convince investors... Key data points include: **First-line:** Safety and primary progression rate from the CAS+zim+ipi cohort; **ORR and PFS curve** from the CAS+zim cohort... - Terry Rosen(CEO)

Contradiction Point 4

First-line Regimen Data Presentation Focus

Contradiction on which data points are prioritized for the first-line regimen's initial data presentation.

Jonathan Miller (Evercore ISI) - Jonathan Miller (Evercore ISI)

2026Q2: The **most critical early readouts** are **safety** and the **rate of primary progression**... The **PFS curve shape** from the Cas plus Zim cohort... will provide early insight... - Terry Rosen(CEO)

Why are you reluctant to share ORR readouts for the Cas, Ipi, and Nevo triplet in the first-line cohort at the October event? - Li Watsek (Cantor / Mizuho)

2026Q1: Initial data... are expected in the fall. The focus is on safety data and the rate of primary progression. Early ORR data is not critical... - Richard Markus(CMO)

Contradiction Point 5

Second-line Regimen Data Presentation and Benchmarking

Contradiction on the benchmark used for PFS data presentation in the second-line study.

Lee Wastick (Kantor) - Lee Wastick (Kantor)

2026Q2: The study design includes a **clean comparison** to see how CasDataFan enhances Cabo's benefit... The company will use **comparative data sets** (including the Cabo Point study)... - Terry Rosen(CEO)

How does prior Lenvatinib exposure affect patient populations in the second-line Cas plus Cabo study versus the LightSpark 011 trial, and what PFS benchmark is appropriate? - Emily Bodnar (H.C. Wainwright)

2026Q1: Confidence in a superior profile already exists, which is why the PEAK-1 Phase III trial is underway. The upcoming updated data will include landmark PFS, ORR, and Kaplan-Meier curves, allowing direct comparison to cabo. - Bob Goeltz(CFO)